Lv2
200 积分 2023-01-12 加入
Inhibition of USP7 enhances CD8+ T cell activity in liver cancer by suppressing PRDM1-mediated FGL1 upregulation
1天前
待确认
Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
1个月前
已完结
Tebentafusp: First Approval
1个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
1个月前
已完结
Mosunetuzumab: First Approval
1个月前
已完结
Mosunetuzumab for the treatment of follicular lymphoma
1个月前
已完结
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
1个月前
已完结
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia
1个月前
已完结
ADCC enhancement: A conundrum or a boon to mAb therapy?
2个月前
已完结
Living in LALA land? Forty years of attenuating Fc effector functions
2个月前
已完结
皖公网安备34019202002308
